Extrait

Background and study aims Chemotherapy is a type of cancer treatment that can also lead to fertility problems in women of reproductive age. The effects of different types of chemotherapy on fertility are still unknown, and depend on the type of chemotherapy, dosage, duration and the patient's age. Recent studies have found that anti-mullerian hormone (AMH) is a valuable marker of fertility. The aim of this study is to find out about the risks to fertility of chemotherapy drugs and the accuracy of AMH in predicting women's fertility following chemotherapy. Who can participate? Women aged 18 - 43 who have been newly diagnosed with cancer (e.g., breast cancer or lymphoma). What does the study involve? Blood tests are used to assess AMH levels in cancer patients before chemotherapy and at follow up 6, 9 months and 1 year later, compared with healthy volunteers without known fertility problems of the same age. We hope to follow up patients for at least 5 years to assess their fertility following chemotherapy. A medical questionnaire is completed by all participants, giving their views on the information they received during the study. What are the possible benefits and risks of participating? Participants may not directly benefit from taking part in the study, but the results could help with decision-making regarding fertility treatment in the future. Risks of participation include the risks of blood tests. Where is the study run from? Warwick University (UK). When is the study starting and how long is it expected to run for? May 2010 to November 2011. Who is funding the study? Midland Fertility Services Ltd (UK). Who is the main contact? Dr Karolina Palinska-Rudzka [email protected]

Critère d'inclusion

• Topic: National Cancer Research Network, Reproductive Health; Subtopic: All Cancers/Misc Sites; Disease: Miscellaneous

Liens

• isrctn
• ictrp